Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Results Conference Call March 27, 2024 8:30 AM ET

Company Participants

Scott Harris - CMO
Vipin Garg - CEO
Rich Eisenstadt - CFO
Scot Roberts - CSO

Conference Call Participants

Corinne Jenkins - Goldman Sachs
Jonathan Wolleben - JMP
Liisa Bayko - Evercore
Mayank Mamtani - B. Riley
Patrick Trucchio - H.C. Wainwright
Roger Song - Jefferies
Seamus Fernandez - Guggenheim
Yasmeen Rahimi - Piper Sandler

Operator

Good day, ladies and gentlemen, and welcome to the Altimmune Inc. Full Year and Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions]

As a reminder, this call is being recorded. I will now introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin.

Rich Eisenstadt

Thank you, Michelle, and good morning, everyone. Thank you for participating in Altimmune's Full Year and Fourth Quarter 2023 Financial Results and Business Update Conference Call. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer; Scot Roberts, our Chief Scientific Officer; and Scott Harris, our Chief Medical Officer.

Following the prepared remarks, we will hold a question-and-answer session A press release with our lean mass preservation data and our full year and fourth quarter 2023 financial results was issued this morning and can be found on the Investor Relations section of the company's website.

Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

For a discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filings with the SEC. I'd also direct you to read the forward-looking statement disclaimer in our press release issued this morning and now available on our website.

Any statements made on this conference call speak only as of today's date, Wednesday, March 27, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date.

As a reminder, this conference call is being recorded and will be available for audio replay on Altimmune's website.